Clinical trialPhase 2Not yet recruiting
Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
A Multi-cohort Exploratory Study to Evaluate the Efficacy and Safety of Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 30 September 2026
- Expected end
- 30 April 2030
- Enrollment
- 147 participants
- Sites
- 1
- Primary outcomes
- Progression-Free Survival (PFS); 1-Year Event-Free Survival Rate (1y-EFS Rate); Recommended Phase 2 Dose (RP2D); Disease-Free Survival (DFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 18 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try